Format

Send to

Choose Destination
Alzheimer Dis Assoc Disord. 2013 Oct-Dec;27(4):302-9. doi: 10.1097/WAD.0b013e31828cc357.

Neurodegenerative disease phenotypes in carriers of MAPT p.A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease.

Author information

1
*Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA †Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, ON, Canada ‡Department of Neurology and Neurosciences, Brain Dynamics Research Center, Dokuz Eylül University, İzmir, Turkey §BEYINMER, Istanbul Kultur University, Istanbul, Turkey ∥Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 'Marqués de Valdecilla' University Hospital, Institute for Formation and Research of the Foundation 'Marqués de Valdecilla' (IFIMAV), University of Cantabria, Cantabria, Spain ¶Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Gipuzkoa, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), area 6, Institute Carlos III, Spain; Neuroscience Area, Institute Biodonostia, San Sebastian, Gipuzkoa, Spain #Department of Neurology, Neurobehavior Division, University of California, Los Angeles **Department of Psychiatry and Neurology, University of California, Los Angeles, CA ††Department of Neuroscience, Mayo Clinic, Rochester, MN ‡‡Department of Medicine, Weill Medical College of Cornell University, New York, NY.

Abstract

Recently, Coppola and colleagues demonstrated that a rare microtubule-associated protein tau (MAPT) sequence variant, c.454G>A (p.A152T) significantly increases the risk of frontotemporal dementia (FTD) spectrum disorders and Alzheimer disease (AD) in a screen of 15,369 subjects. We describe clinical features of 9 patients with neurodegenerative disease (4 women) harboring p.A152T, aged 51 to 79 years at symptom onset. Seven developed FTD spectrum clinical syndromes, including progressive supranuclear palsy syndrome (n=2), behavioral variant FTD (bvFTD, n=1), nonfluent variant primary progressive aphasia (nfvPPA, n=2), and corticobasal syndrome (n=2); 2 patients were diagnosed with clinical AD. Thus, MAPT p.A152T is associated with a variety of FTD spectrum clinical presentations, although patients with clinical AD are also identified. These data warrant larger studies with clinicopathologic correlation to elucidate the influence of this genetic variant on neurodegenerative disease.

PMID:
23518664
PMCID:
PMC3796183
DOI:
10.1097/WAD.0b013e31828cc357
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center